HPV-targeting cell therapy tested for advanced cervical cancer
NCT ID NCT05357027
First seen Jan 22, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This early-phase trial tested a new cell therapy called TC-E202 for people with advanced cervical cancer that had stopped responding to standard treatments. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells infected with HPV type 16. The study was terminated early after enrolling only 5 participants, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xiaochun Cheng
Chongqing, Chongqing Municipality, 400000, China
Conditions
Explore the condition pages connected to this study.